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DNA methylation age is an accurate biomarker of chronological age and predicts lifespan, but
its underlying molecular mechanisms are unknown. In this genome-wide association study of
9907 individuals, we ﬁnd gene variants mapping to ﬁve loci associated with intrinsic epi-
genetic age acceleration (IEAA) and gene variants in three loci associated with extrinsic
epigenetic age acceleration (EEAA). Mendelian randomization analysis suggests causal
inﬂuences of menarche and menopause on IEAA and lipoproteins on IEAA and EEAA. Var-
iants associated with longer leukocyte telomere length (LTL) in the telomerase reverse
transcriptase gene (TERT) paradoxically confer higher IEAA (P< 2.7 × 10−11). Causal mod-
eling indicates TERT-speciﬁc and independent effects on LTL and IEAA. Experimental hTERT-
expression in primary human ﬁbroblasts engenders a linear increase in DNA methylation age
with cell population doubling number. Together, these ﬁndings indicate a critical role for
hTERT in regulating the epigenetic clock, in addition to its established role of compensating
for cell replication-dependent telomere shortening.
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DNA methylation (DNAm) proﬁles of sets of cytosinephosphate guanines (CpGs) allow one to develop accurateestimators of chronological age which are referred to as
“DNAm age”, “epigenetic age”, or the “epigenetic clock”. Across
the life course the correlation between DNAm age and
chronological age is >0.951,2. Individuals whose leukocyte DNAm
age is older than their chronological age (“epigenetic age
acceleration”) display a higher risk of all-cause mortality after
accounting for known risk factors3–6, and offspring of
centenarians exhibit a younger DNAm age7. Epigenetic age
acceleration in blood is associated with cognitive impairment,
neuro-pathology in the elderly8,9, Down syndrome10, Werner
syndrome11, Parkinson’s disease12, obesity13, HIV infection14,
and frailty15, menopause16 but it only displays weak correlations
with clinical biomarkers17,18. DNAm age shows no apparent
correlation with leukocyte telomere length (LTL), whose pace of
shortening in cultured somatic cells has been referred to as the
‘mitotic clock’. In vivo, DNAm age and telomere length appear to
be independent predictors of mortality19.
Here we examine two widely used measures of epigenetic age
acceleration: (a) intrinsic epigenetic age acceleration (IEAA),
based on 353 CpGs described by Horvath2, which is independent
of age-related changes in blood cell composition, and (b) extrinsic
epigenetic age acceleration (EEAA), an enhanced version of that
based on 71 CpGs described by Hannum (2013) which up-
weights the contribution of blood cell count measures1,6. IEAA
and EEAA are only moderately correlated (r = 0.37). IEAA
measures cell-intrinsic methylation changes, exhibits greater
consistency across different tissues, appears unrelated to lifestyle
factors and probably indicates a fundamental cell aging process
that is largely conserved across cell types2,6. By contrast, EEAA
captures age-related changes in leukocyte composition and
correlates with lifestyle and health-span related characteristics,
yielding a stronger predictor of all-cause mortality6,18. To dissect
the genetic architecture underlying DNAm age of blood, we
performed genome-wide association studies (GWAS) of
IEAA and EEAA based on leukocyte DNA samples from almost
10,000 individuals. Our GWAS identiﬁes a total of ﬁve
loci associated with IEAA and three loci associated with
EEAA at genome-wide signiﬁcance. One of the loci associated
with IEAA co-locates with the Telomerase Reverse Transcriptase
(TERT) gene on chromosome 5. Variants in TERT that are
associated with increased IEAA are also associated with longer
telomeres. Our in vitro experiments indicate that hTERT
expression is required for DNAm aging in human primary
ﬁbroblast cells. Finally, our Mendelian randomization analyses
reveal that age at menarche and age at menopause have a causal
effect on IEAA.
Results
GWAS meta-analyses for IEAA and EEAA. Genomic analyses
were performed in 9907 individuals (aged 10–98 years), from 15
data sets, adjusted for chronological age and sex (Supplementary
Table 1, Fig. 1, and Supplementary Note 1). Eleven data sets
comprised individuals of European ancestry (84.7%) and four
comprised individuals of African (10.3%) or Hispanic ancestry
(5.0%). GWAS genotypes were imputed to ~7.4 million variants
using the 1000 genomes reference panel. To estimate the herit-
ability of epigenetic age acceleration in blood, we used both
pedigree- and SNP-based methods (Methods section). Our
pedigree-based estimates of heritability were h2IEAA = 0.37 and
h2EEAA = 0.33 in individuals of European ancestry, which is con-
sistent with previous heritability estimates in twins2 and with
those obtained in other tissues (e.g., adipose and brain)9,13,20.
SNP-based estimates of heritability in our European ancestry
cohorts were lower, h2IEAA = 0.19 and h
2
EEAA = 0.19 (Supplementary
Table 2).
We ﬁrst performed GWAS meta-analysis of IEAA and EEAA
only in our European ancestry cohorts (N = 8393). Variants with
suggestive associations (P< 1.0 × 10−5) were then evaluated in
non-European ancestry cohorts (N = 1514), followed by a
combined meta-analysis across the two strata (Fig. 1a, b). We
found no evidence for genomic inﬂation in individual studies
(λGC ¼ 0:99 ~ 1.06, Supplementary Tables 3 and 4) or in the
European ancestry meta-analysis (λGC = 1.03 ~ 1.05; LD score
regression (LDSC) intercept terms β0;IEAA ¼ 1:004 and
β0;EEAA ¼ 1:004; Supplementary Fig. 1 and Supplementary
Table 2). Variant associations that were genome-wide
signiﬁcant (P< 5.0 × 10−8) according to the ﬁxed-effect meta-
analysis were also evaluated with the trans-ethnic heterogeneity
test that is implemented in the MANTRA software21. The
MANTRA software provides a meta-analysis estimate, known as
Bayes Factor (BF), that is arguably more stringent than the ﬁxed-
effects meta-analysis because it accounts for genetic heterogeneity
between different study populations. Our study focused on
genetic variants that met two criteria: ﬁxed effects meta
P< 5.0 × 10−8 and MANTRA log10BF  6 (≅P< 5 × 10−8).
For IEAA, we identiﬁed 264 associated variants, mapping to ﬁve
genomic loci (3q25.33, 5p15.33, 6p22.3, 6p22.2, and 17q22,
Table 1, Supplementary Data 1, Fig. 2, and Supplementary Fig. 2).
Conditional analyses revealed a secondary signal for IEAA at
6p22.3 (Table 1, Supplementary Figs. 3c and h). For EEAA, we
identiﬁed 440 associated variants, mapping to three loci (4p16.3,
10p11.1, and 10p11.21; Table 1, Supplementary Data 1, Fig. 2, and
Supplementary Fig. 4); however, the two lead SNPs, rs71007656
and rs1005277 at 10p11.1 and 10p11.21, respectively, are
moderately correlated (r2EUR = 0.35, Table 1). Conditional analysis
showed that the association of the INDEL variant rs71007656
partially derived from its association with rs1005277 because the
P-value of rs71007656 was no longer genome-wide signiﬁcant in a
conditional model of rs1005277. By contrast, the SNP rs1005277
remained genome-wide signiﬁcant in a conditional model of
rs71007656 (Supplementary Fig. 5b, c and e, f). Associations were
consistent across studies (Supplementary Figs. 6 and 7), except for
one locus (6p22.3: Cochran’s I2 = 58%, MANTRA posterior
probability of heterogeneity = 0.64, Table 1 and Supplementary
Data 1). At each of the ﬁve IEAA related loci, the risk alleles
conferred between 0.41 and 1.68 years higher IEAA (Table 1). Of
the ﬁve loci associated with IEAA, four also exhibited at least
suggestive and sign-consistent associations with EEAA (most
signiﬁcant P = 6.6 × 10−7, Supplementary Data 2. By contrast,
SNPs in the three loci associated with EEAA were not associated
(P> 0.05) with IEAA (Supplementary Data 2). Analysis of
published chromatin state marks22 showed that most lead variants
are in chromosomal regions that are transcribed in multiple cell
lines (Supplementary Fig. 8). Two loci, 6p22.2 and 6p22.3, co-
locate (within 1Mb) with CpGs that contribute to the Horvath
estimate of DNAm age (Table 1 and Supplementary Data 1), and
it is possible that these genotypic associations with IEAA arise
from direct SNP effects on local methylation (Supplementary
Note 2 and Supplementary Figs. 9 and 10).
Transcriptomic studies in leukocytes. To learn about potential
functional consequences of these associations, we conducted
cis-eQTL analysis for each locus associated with IEAA or EEAA,
using data on leukocyte mRNA expression in up to 15,295
samples from ﬁve studies (Fig. 1c; Methods section). We identiﬁed
11 putative cis-eQTLs located in seven of the eight associated loci
(Supplementary Data 3). Each putative cis-eQTL was then
analyzed by summary data-based Mendelian randomization
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Fig. 1 Roadmap for studying genetic variants associated with epigenetic age acceleration in blood. The roadmap depicts our analytical procedures. a The
study sets were divided into two stages according to European (EUR) and non-European ancestry. b Stage 1 yielded GWAS summary data on all QC SNPs
and the combined stage yielded GWAS summary data on the SNPs with Meta EUR P< 1.0 × 10−5 at stage 1. Genome-wide signiﬁcant loci were determined
based on the association results from the combined stage. c Describes our transcriptomic studies: (I) blood cis-eQTL to identify potential functional genes,
(II) summary statistics based Mendelian randomization (SMR) to assess the causal associations between expression levels and IEAA (or EEAA). d
Describes our detailed analysis in the TERT locus, which was implicated by our GWAS of IEAA. Bidirectional Mendelian randomization via MR-Egger
analysis did not reveal a direct causal effect between leukocyte telomere length and IEAA. Our in vitro studies validate our genetic ﬁndings by
demonstrating that hTERT over-expression promotes epigenetic aging in e. To explore molecular pathways underlying epigenetic age acceleration, we
conducted gene set enrichment analysis, as listed in f. Finally, we performed LDSC genetic correlation between IEAA or EEAA and a broad category of
complex traits, followed by MR-Egger regression analysis, as depicted in g. Abbreviations: GE= gene expression, LTL= leukocyte telomere length
NATURE COMMUNICATIONS | DOI: 10.1038/s41467-017-02697-5 ARTICLE
NATURE COMMUNICATIONS |  (2018) 9:387 |DOI: 10.1038/s41467-017-02697-5 |www.nature.com/naturecommunications 3
(SMR), which infers the association between gene transcript levels
and the outcome trait23 (Methods section). Three transcripts were
associated with IEAA: KPNA4 at 3q25.33, TPMT at 6p22.3 and
STXBP4 at 17q22; and three transcripts were associated with
EEAA: RNF4 at 4p16.3, ZNF25 at 10p.21, and HSD17B7P2 at
10p11.21 and 10p11.1 (Table 2 and Supplementary Table 5).
Notably, STXBP4, encoding the syntaxin-binding protein, is a
reported locus for age at menarche24, and our lead SNP for IEAA
was also associated with age at menarche (rs78781855, P = 0.0002).
Paradoxical SNP association between IEAA and LTL in TERT.
The TERT locus (in 5p15.33) harbored 11 genome-wide sig-
niﬁcant SNPs for IEAA but conditional analysis did not reveal
any secondary signal (Table 1, Fig. 3a, and Supplementary
Data 1). The leading SNP, rs2736099, was located in a region
transcribed in human embryonic stem cells, induced pluripotent
stem cells, and hematopoietic stem cells (Supplementary Fig. 8b),
and each minor allele conferred 0.6 years higher IEAA (P = 1.3 ×
10−12; Table 1, Supplementary Fig. 6b). Our IEAA locus at TERT
closely overlaps the reported GWAS locus for LTL25–27 (Fig. 3b).
To further demonstrate that our GWAS ﬁndings surrounding
TERT and IEAA are not mediated by LTL, we carried out an
additional GWAS analysis of an LTL adjusted measure of IEAA
in the subset (n = 785) of individuals for whom both IEAA and
LTL were available. As expected, the LTL adjusted measure of
IEAA continued to exhibit signiﬁcant associations with the var-
iants in the TERT locus (Methods section and Supplementary
Fig. 11).
SMR analysis indicated that the association signals for LTL and
IEAA at this TERT locus share the same underlying causal variant
(as indicated by a non-signiﬁcant HEIDI test, Supplementary
Table 6, Supplementary Fig. 12c). Intriguingly, TERT alleles
associated with a longer LTL were robustly associated with
increased IEAA (P ~ 1.0 × 10−11, Table 3, Supplementary Table 7,
and Supplementary Fig. 13).
Other known GWAS LTL signals (at 10q24.33 near OBFC1
and at 16q23.3 near MPHOSPH6), also exhibited modest
associations with IEAA (4.1 × 10−3 ≤ P ≤ 3.7 × 10−2), but others,
such as the gene TERC (on 3q26.2) encoding the telomerase RNA
component, showed no association (Table 3). Using the lead
variants for each trait in MR-Egger analyses28, we found
pleiotropic effects speciﬁc to TERT on LTL and IEAA without
evidence for a causal relationship between LTL and IEAA
(P = 0.7), Table 4 and Supplementary Table 8.
Blood cell composition vs. variants in TERT. By deﬁnition,
IEAA is independent of various blood cell count estimates, i.e., it
does not correlate with imputed blood cell abundance measures
Table 1 Meta-analysis of GWAS of epigenetic age acceleration in blood
Fixed-effects Trans-ethnic
Band NGWAS SNP Gene Mb A1/A2 MAF Stage Beta (SE) P-value I2 log10BF PHET.
IEAA
3q25.33 23 rs11706810 TRIM59 160.2 C/T 0.45 EUR 0.40 (0.07) 2.8 × 10−8
Non-EUR 0.44 (0.19) 1.8 × 10−2
Combined 0.41 (0.07) 1.6 × 10−9 3% 7.5 0.26
5p15.33 11 rs2736099 TERT 1.3 A/G 0.36 EUR 0.64 (0.09) 4.7 × 10−12
Non-EUR 0.50 (0.30) 9.9 × 10−2
Combined 0.63 (0.09) 1.3 × 10−12 0% 10.6 0.47
6p22.3 104 rs143093668a KIF13A-NHLRC1 18.1 T/C 0.05 EUR −1.78 (0.10) 1.9 × 10−21
Non-EUR −1.37 (0.33) 2.4 × 10−5
Combined −1.68 (0.16) 4.2 × 10−25 58% 23.1 0.64
rs6915893b,c KIF13A-NHLRC1 18.1 T/C 0.39 EUR 0.56 (0.08) 5.1 × 10−13
Non-EUR 0.33 (0.17) 5.8 × 10−2
Combined 0.52 (0.07) 1.6 × 10−13 27% 11.4 0.34
6p22.2 108 rs73397619d LRRC16A-SCGN 25.6 C/T 0.29 EUR −0.46 (0.08) 5.9 × 10−9
Non-EUR −0.46 (0.18) 1.2 × 10−2
Combined −0.46 (0.03) 2.3 × 10−10 18% 8.3 0.32
17q22 18 rs78781855 STXBP4 53.1 G/T 0.22 EUR −0.42 (0.09) 1.6 × 10−6
Non-EUR −0.88 (0.23) 1.5 × 10−4
Combined −0.47 (0.08) 5.6 × 10−9 26% 7.2 0.45
EEAA
4p16.3 59 rs10937913 TNIP2 2.8 A/G 0.46 EUR −0.60 (0.01) 3.8 × 10−10
Non-EUR −0.56 (0.23) 1.4 × 10−2
Combined −0.59 (0.09) 1.7 × 10−11 0% 9.2 0.24
10p11.21 59 rs71007656 ANKRD30A-ZNF248 40.0 R/Ie 0.49 EUR 0.61 (0.1−) 1.1 × 10−9
Non-EUR 0.52 (0.22) 2.0 × 10−2
Combined 0.59 (0.09) 7.5 × 10−11 0% 8.5 0.29
10p11.1 322 rs1005277 ZNF248-ZNF25 38.2 A/C 0.28 EUR 0.78 (0.11) 2.6 × 10−13
Non-EUR 0.45 (0.29) 1.1 × 10−1
Combined 0.74 (0.10) 1.2 × 10−13 32% 11.5 0.32
Position Mb based on Hg19 assembly
Lead SNPs at genome-wide signiﬁcant (P < 5.0 × 10−8) loci for IEAA or EEAA. Epigenetic Clock CpGs that co-locate within ±1 Mb of the leading variant are listed in the footnote. Fixed effects meta-
analysis was used to estimate the effect size (Beta) and standard error (SE) on IEAA or EEAA per minor allele. Trans-ethnic analyses using MANTRA21 present ethnicity-adjusted associations (log10
Bayes’ Factor (BF) and probability of heterogeneity across studies (PHET.)
NGWAS= number of GWAS markers, A1/A2=minor/major alleles, MAF=mean of minor allele frequency estimates across studies weighted by study sample sizes, I2= Cochran’s I2. Beta estimate is the
regression coefﬁcient with respect to each extra minor allele
a The CpG predictor cg22736354 for epigenetic clock is located 8.5 kb from the leading variant
b The CpG predictor cg22736354 for epigenetic clock is located 12.2 kb from the leading variant
c Conditional analysis on rs143093668 (LD EUR r2= 0.02): Beta(SE)= 0.39 (0.069) with effect size dropped 26% and conditional Meta P-value at combined phase= 2.6 × 10−8
d The CpG predictor cg06493994 for epigenetic clock is located 27.8 kb from the leading variant
e Reference/insertion alleles= C/CGGCTG
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(Methods section). By contrast, LTL exhibits the expected positive
correlation with the abundance of naive CD8+ T cells
(r = 0.22, P = 4.6 × 10−10) and naive CD4+ T cells (r = 0.13,
P = 0.00026) even after adjusting for chronological age (Supple-
mentary Fig. 14). Consistent with our paradoxical association
between LTL-related SNPs and IEAA, we ﬁnd that TERT variants
associated with a higher abundance of naive T cells (indicative of
a younger adaptive immune system) are positively associated with
higher values of IEAA and higher values of EEAA (indicative of
an older epigenetic age, Supplementary Figs. 15 and 16, and
Supplementary Data 4). However, none of the SNPs in the TERT
locus was signiﬁcantly associated with cell counts after correcting
for multiple comparisons (uncorrected P> 0.003, Supplementary
Data 4) despite of the large sample size N> 5000.
hTERT is required for DNAm aging in human primary cells.
As we were unable to functionally link IEAA to TERT through
cis-eQTL analysis at 5p15.33, we examined the effects of experi-
mentally induced hTERT expression on IEAA in a primary
human cell culture model. We introduced a TERT-expressing
vector or empty vector (as control) into primary ﬁbroblasts iso-
lated from human neonatal foreskin. Transduced TERT-expres-
sing and non-TERT cells were cultured in parallel. Upon reaching
conﬂuence, the cells were collected, counted, seeded into fresh
plates, and proﬁled using the Illumina Inﬁnium 450K DNA
methylation array.
While non-TERT cells senesced after ~150 days, TERT-
expressing cells continued to proliferate unabated at a constant
rate with time in culture (Fig. 3c). Single-time point analyses
(Fig. 3d) showed that TERT-expressing cells exhibited a linear
relationship between time in culture and the Horvath estimate of
DNAm age (equivalent to a DNAm age of 50 years at 150 days),
whereas in non-TERT cells DNAm age plateaued (equivalent to a
DNAm age of 13 years) in spite of continued proliferation to the
point of replicative senescence. Notably, DNAm age did not
increase in TERT-expressing cells that received regular media
change but were not passaged throughout the entire observation
period of 170 days (right most bar in Fig. 3d). These cells were
not senescent, given that their subsequent passaging resulted in
normal proliferation. In multivariable regression analysis, the
associations of DNAm age with cell passage number and cell
population doubling number were highly modiﬁed by TERT-
expression (P-interaction: P = 1.6 × 10−6 and P = 4.0 × 10−5,
respectively; Supplementary Table 9). In the absence of TERT-
expression, DNAm age did not increase with cell passage number,
cell population doubling number, or time in culture.
Other putative determinants of epigenetic age acceleration. To
systematically elucidate possible further biological processes that
inﬂuence epigenetic age acceleration, we tested our full genome-
wide association statistics for IEAA and EEAA using a number of
approaches. First, we used MAGENTA29 (Methods section) to
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identify biological pathways that are enriched for genes that
harbor associated variants. For IEAA, nuclear transport (FDR =
0.017), Fc epsilon RI signaling (FDR = 0.027), and colorectal
cancer processes (FDR = 0.042) were implicated. For EEAA,
mRNA elongation (FDR = 0.011), mRNA transcription (FDR =
0.018), and neurotrophin signaling pathway (FDR = 0.042) were
implicated (Supplementary Table 10). The GO gene set involved
in telomere maintenance showed nominally signiﬁcant enrich-
ment with IEAA (P = 0.04, Supplementary Table 11), which is
consistent with our results surrounding the overlap between
IEAA and telomere length associated genes.
Second, we explored the genetic correlations (rg) between IEAA
or EEAA and 27 phenotypes using LD score regression analysis of
summary level GWAS data30 (Methods section and Fig. 1g). We
observed moderate positive genetic correlation between IEAA
and EEAA (rg = 0.5, Prg = 8.9 × 10
−3). IEAA showed weak positive
genetic correlations with central adiposity (waist circumference)
and metabolic disease-related traits, and EEAA showed stronger
positive genetic correlations with central adiposity (rg = 0.15 with
waist circumference, P = 9.0 × 10−4) and metabolic disease-related
traits (Table 4 and Supplementary Table 12). IEAA and EEAA
also showed modest inverse genetic correlations with age at
menopause.
Further, we performed a genetic correlation analysis using all
available GWAS summary data from the LD Hub platform31 (see
URL), identifying additional traits at nominal signiﬁcance levels
(P< 0.05). Lung function measures (forced expiratory volume)
and brain volume measures exhibited negative genetic correla-
tions with both IEAA and EEAA (Supplementary Data 5).
Further, IEAA exhibited a positive genetic correlation rg with
primary sclerosing cholangitis and a negative genetic correlation
with father’s age at death.
Third, we performed MAGENTA based hypergeometric
analyses to test whether the top 2.5 and 10% of genes enriched
for GWAS associations with IEAA or EEAA overlap with the top
enriched genes for a range of complex traits (Methods section).
This analysis suggested several additional possible genetic over-
laps, including Huntington disease onset32 and bipolar disorder
with IEAA, schizophrenia with EEAA, and age-related demen-
tia20 with both IEAA and EEAA (Supplementary Data 6).
Finally, all the study traits were tested using MR-Egger
regression which, by modeling the reported top genetic signals
for each candidate trait, estimates the likely causal inﬂuence of
that trait on IEAA or EEAA28 (Methods section). Nominally
signiﬁcant causal relationships on higher IEAA and EEAA were
found for low-density lipoprotein (LDL) and total cholesterol
levels (P< 0.05, Supplementary Tables 13 and 14) and for
triglyceride levels on IEAA (P = 3.0 × 10−2, Table 4). Earlier
menarche and menopause were associated with higher IEAA;
each 1-year earlier age at menarche was associated +1.03 years
higher IEAA (P = 4.1 × 10−3) and each 1-year earlier age at
menopause was associated +0.43 years higher IEAA (P = 3.5 × 10
−3) (Table 4). A sensitivity analysis shows that the observed causal
associations do not result from instrumental variable SNPs co-
locating with CpG sites from DNAm age estimators (Methods
section and Supplementary Table 15). Our MR-Egger analysis
revealed a causal effect of IEAA on a rough proxy of life span
(father’s age at death) (P = 1.9 × 10−2, Supplementary Table 16),
which is consistent with previous studies that demonstrated that
epigenetic age acceleration predicts life span3–7.
Discussion
This large genomic study provides several insights into the reg-
ulation of epigenetic aging, including apparently opposing roles
for TERT on DNAm age and LTL. TERT encodes the catalytic
subunit of telomerase, which counters telomere shortening during
cell division33. TERT also possesses activities unrelated to telo-
mere maintenance, such as in DNA repair, cell survival, protec-
tion from apoptosis or necrosis, stimulation of growth34–36 and
cell proliferation, possibly by decreasing p21 production37. Here
we show an additional pleiotropic role of TERT on advancing cell
intrinsic DNAm age during cell proliferation. Our ﬁndings pro-
vide an explanation for the previously reported rapid rate of
DNAm aging during embryonic development and early postnatal
life, which are stages of rapid organismal growth accompanied by
high levels of TERT activity and cell division38–40.
The paradoxical ﬁnding that TERT alleles associated with
longer telomeres are associated with higher IEAA is supported by
(a) signiﬁcant meta-analysis P-values, (b) validation in multiple
large cohort studies, (c) in vitro support using primary ﬁbroblasts,
(d) consistent associations of other LTL associated genes (OBFC1
and MPHOSPH6), and (e) consistent genetic associations with
select leukocyte subsets (e.g., naive T cells). While the paradoxical
Table 2 Summary of transcriptomic studies for loci associated with epigenetic age acceleration
Meta GWAS cis-eQTL SMR
Band SNP P-value (sign) Database Gene P-value (sign) P-value (sign)
IEAA
3q25.33 rs11706810 1.6 × 10–9 (+) FHS KPNA4 4.2 × 10–23 (+) 5.1 × 10−5 (+)
6p22.3 rs6915893 1.6 × 10–13 (+) FHS TPMT 6.0 × 10–14 (+) 1.1 × 10−7 (+)
GTEx 1.5 × 10–4* (+) 2.2 × 10−6 (+)
LSMeta 2.3 × 10–27 (+) 3.5 × 10−7 (+)
17q22 rs78781855 5.6 × 10–9 (–) FHS STXBP4 1.0 × 10–88 (–) 6.2 × 10−4 (+)
EEAA
4p16.3 rs2341303a 6.5 × 10–11 (–) LSMeta RNF4 1.6 × 10–10 (–) 2.0 × 10−3 (+)
10p11.21 rs71007656 7.5 × 10–11 (+) FHS ZNF25 7.9 × 10–7 (+) 2.8 × 10−3 (+)
GTEx HSD17B7P2 3.0 × 10–8 (+) 6.9 × 10−6 (+)b
10p11.1 rs1005277 1.2 × 10–13 (+) GTEx HSD17B7P2 1.1 × 10–5 (+) 6.9 × 10−6 (+)b
Bands corresponding the position of Meta GWAS SNP
The table presents a total of six cis genes highlighted from transcriptomic study using three large-scale databases (N= 10,906), including (1) FHS (N= 5257), (2) GTEx (N= 338), and (3) LSMeta (5311).
Each cis gene exhibited signiﬁcant cis-eQTL with several nearby GWAS SNPs at FDR q< 0.05 in at least one study and also showed a signiﬁcant pleiotropic association in SMR analysis at P< 0.05 after
Bonferroni correction. For each gene, we list the unadjusted P-values (sign) from Meta GWAS for IEAA (or EEAA), cis-eQTL and SMR analysis. The column (sign) indicates the sign of Z-statistic at each
test while the test alleles were converted to the same alleles (with minor variants) for both Meta GWAS and cis-eQTL tests. The summary statistics of Meta GWAS and cis-eQTL are both based on the
leading marker with the most signiﬁcant P-value in a given locus, according to the GWAS results
* FDR> 0.05 but FDR< 0.05 associated with other GWAS SNPs (Supplementary Data 3)
a The SNP rs2341303 is a surrogate of the leading marker rs10937913 in 4p16.3 (LD r2EUR = 0.98)
b The SMR results are derived from the same model as the analysis used the cis SNPs of the gene HSD17B7P2
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ﬁnding cannot be disputed on scientiﬁc grounds, its biological
interpretation remains to be elucidated. In our genetic studies, we
found no evidence for a broader causal inter-relationship between
telomere length and IEAA consistent with the lack of phenotypic
association between these traits in our studies (WHI: r = −0.05,
P = 0.16; FHS: r = 0.0, P = 0.99, ref. 41) and in previous
reports15,19. The lack of a phenotypic association between LTL
and IEAA indicates that the shared genetic inﬂuence (due to
TERT and, to a lesser extent, OBFC1 andMPHOSPH6) is dwarfed
by environmental inﬂuences acting on these traits.
While critically short telomere length is a well-established
trigger of replicative senescence38,42–44, the functional con-
sequences of epigenetic aging are yet unknown. Our experimental
data suggest that epigenetic aging is not a determinant or marker
of cell replicative senescence, since TERT-expressing cells con-
tinued to proliferate unabatedly despite well-advanced DNAm
age, and non-TERT-expressing cells exhibited no DNAm age
increase even at days 120–170 when proliferation had ceased and
the cells had become senescent. Rather, TERT expression appears
to allow cells to record their proliferation history. Our experi-
ments show a clear association between DNAm age with cumu-
lative population doubling (and days in culture) of cells with
experimentally induced hTERT expression. This was not the case
with proliferating cells that do not express hTERT. While the
mechanism is yet to be elucidated, preliminary evidence suggests
that DNAm age does indeed track the cell division of stem/pro-
genitor cells, e.g., passage number is highly correlated with
DNAm age of mesenchymal stem cells2,45.
Large-scale cross-sectional cohort studies have previously
reported associations between epigenetic age acceleration (IEAA
and EEAA) and body mass index and measures of insulin resis-
tance18. Our genetic correlation analyses (between the measures
of age acceleration and complex phenotypes) indicate that some
of these associations may arise in part from shared genetic var-
iants. The genetic correlation between IEAA and EEAA is quite
high (rg = 0.52, P = 0.0089) considering that these epigenetic
biomarkers are based on distinct sets of CpGs and exhibit only
modest phenotypic correlations (r = 0.37 in the WHI and r = 0.36
in the FHS). By contrast, IEAA/EEAA exhibit only relatively weak
genetic correlations with many age related traits for a variety of
reasons, including (i) technical variation/noise in the measures of
epigenetic age acceleration, (ii) relatively low sample size in our
GWAS of IEAA/EEAA, (iii) blood methylation data only provide
insufﬁcient information for capturing the dysfunction of other
organ systems. The latter point is illustrated by the ﬁnding that
obesity has a strong effect on the epigenetic age of liver tissue but
only a weak effect on the epigenetic age of blood tissue13,18.
Our Mendelian randomization analyses provided tentative
evidence for causal inﬂuences for blood lipid levels, but not for
adiposity, on IEAA and EEAA. The suggestive causal effect of
educational level on EEAA and the negative genetic correlation
(r = −0.13, P = 1.0 × 10−3) are consistent with the previously
observed phenotypic correlation between these traits18.
Finally, we found evidence for causal inﬂuences of earlier ages
at menarche and menopause on higher IEAA. The directionally
concordant inﬂuences of menarche and menopause, which signal
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Fig. 3 Genetic analysis of the 5p15.33 TERT locus and in vitro studies of hTERT in ﬁbroblasts. a Regional association plot of locus associated with IEAA. The
y-axis depicts log-transformed meta-analysis P-values across all studies 1–15. The colors visualize linkage disequilibrium (LD) r2 between rs2736099
(colored in purple) and neighboring SNPs. b TERT-locus association with IEAA (marked in red) overlaid with the association with leukocyte telomere
length (LTL) given by Bojesen et al.25 (marked in blue). Note that several SNPs in the TERT locus are associated with both IEAA and leukocyte telomere
length at a genome-wide signiﬁcant level. c Growth of human primary ﬁbroblasts (n= 46) represented as population doublings (y-axis) vs. days in culture
(x-axis). d Adjusted epigenetic age of n= 14 individual samples (y-axis) vs. days in culture (x-axis). The adjusted age estimate was deﬁned as difference
between Horvath DNAm age minus 28 years, since the former exhibited a substantial offset in ﬁbroblasts. DNAm ages are increased in the hTERT
expressing cells in the four later time points (days 97, 117, 131, and 159) resulting in a paired Student's t-test P-value of 0.043. However, no increase in
DNAm age can be observed in cells that are static (last bar)
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the onset and cessation, respectively, of reproductive capacity,
together with the lack of inﬂuence of any measure of adiposity on
IEAA, suggest an effect of some yet identiﬁed driver of repro-
ductive aging on DNAm aging. These ﬁndings, which suggest that
sex steroids affect epigenetic aging, are consistent with previously
reported associations regarding early menopause timing and
higher IEAA in blood16. While menopausal hormone therapy was
not found to be associated with IEAA in blood, it was found to be
associated with younger epigenetic age acceleration in buccal
epithelium16. The effect of menopause is consistent with reported
anti-aging effects of sex hormone therapy on buccal cells and the
pro-aging effect of surgical ovariectomy in blood16. Early age at
menarche, a widely studied marker of the timing of puberty in
females, is associated with higher risks for diverse diseases of
aging46. Our ﬁndings indicate epigenetic aging as a possible
intrinsic mechanism that underlies the recently described link
between menarche age-lowering alleles and shorter lifespan47.
Methods
GWAS Cohorts. GWAS meta-analysis was performed on 9907 individuals across
15 studies (Supplementary Table 1) coming from eight cohorts: Framingham Heart
Study (FHS), TwinsUK, Women’s Health Initiate (WHI), European Prospective
Investigation into Cancer–Norfolk (EPIC-Norfolk), Baltimore Longitudinal Study
of Aging (BLSA), Invecchiare in Chianti, aging in the Chianti Area Study
(inCHIANTI), Brisbane Systems Genetics Study (BSGS), and Lothian Birth
Cohorts of 1921 and 1936 (LBC) (Supplementary Note 1). Eleven data sets com-
prised individuals of European ancestry (EUR, 84.7%) and four data sets comprised
individuals of African ancestry (AFR, 10.3%) or Hispanic ancestry (AMR, 5.0%).
Age range was 10–98 years (69% females).
DNA methylation age and measures of age acceleration. By contrasting the
DNAm age estimate with chronological age, we deﬁned measures of epigenetic age
acceleration that are uncorrelated with chronological age. We evaluated two types
of measures of epigenetic age acceleration in blood: cell-intrinsic and extrinsic
epigenetic measures, which are independent of, or related to blood cell counts,
respectively. Intrinsic epigenetic age acceleration (IEAA) is deﬁned as the residual
resulting from regressing the DNAm age estimate from Horvath (353 CpG mar-
kers) on chronological age and blood cell count estimates. By deﬁnition, IEAA does
not depend on blood cell counts. By contrast, extrinsic epigenetic age acceleration
(EEAA) depends on blood cell counts because it is deﬁned by up-weighting the
blood cell count contributions to the Hannum’s epigenetic age estimator (71
CpGs). Thus, EEAA captures both age-related changes in blood cell types, as well
as cell-intrinsic age-related changes in DNAm levels.
IEAA and EEAA are based on the DNAm age estimates from Horvath2 (353
CpG markers) and from Hannum et al.1 (71 CpGs), respectively. Mathematical
details and software tutorials for estimating epigenetic age can be found in
Horvath2. By deﬁnition, IEAA is independent of blood immune cell counts (naive
CD8+ T cells, exhausted CD8+ T cells, plasma B cells, CD4+ T cells, natural killer
cells, monocytes, and granulocytes) estimated from DNA methylation data. EEAA
is calculated using the following three steps. First, we calculated the DNAm age
estimate from Hannum et al.1. Second, we increased the contribution of age related
blood cell types to the DNAm age estimate by forming a weighted average of
Hannum’s DNAm age estimate with the following 3 blood cell type estimate: naive
(CD45RA+CCR7+) cytotoxic T cells, exhausted (CD28−CD45RA−) cytotoxic
T cells, and plasmablasts using the Klemera-Doubal approach48. The weights used
in the averaging procedure were chosen on the basis of the WHI data, i.e., the same
weights were used in all data sets. EEAA is positively associated with exhausted
CD8+ T cells, plasmablast cells, and negatively associated with naive CD8+ T cells.
Thus, EEAA tracks both age related changes in blood cell composition and cell-
intrinsic DNAm changes. Both the intrinsic and extrinsic DNAm age measures
were correlated highly with chronological age within each contributing cohort
(0.63 ≤ r ≤ 0.97, Supplementary Table 1), except for the two Lothian birth cohorts
whose participants were born in one of two single years and hence had a small age
range at testing. Conversely, by deﬁnition, our measures of DNAm age
acceleration, IEAA and EEAA, are not associated with chronological age.
The measures of epigenetic age acceleration are implemented in our freely
available software (https://dnamage.genetics.ucla.edu)2.
Estimating blood cell counts based on DNA methylation levels. The blood cell
abundance measures were estimated using two different methods. The proportions
of cytotoxic (CD8+) T cells, helper (CD4+) T, natural killer, B cells, and granulo-
cytes were estimated with the Houseman method49. The percentage of exhausted
CD8+ T cells (deﬁned as CD28−CD45RA−), the number (count) of naive CD8+
T cells (deﬁned as CD45RA+CCR7+), and plasma blasts were estimated with the
Horvath method14. These DNAm based estimates of blood cell counts are highly
correlated with corresponding ﬂow cytometric measures50.
Heritability analysis. Both IEAA and EEAA measures were adjusted for sex prior
to estimation of heritability. We conducted heritability analysis using three
approaches: (1) SOLAR (Sequential Oligogenic Linkage Analysis Routine)51 based
on pedigree data, (2) LDSC (LD score regression)30 based on GWAS summary
data, and GCTA (Genome-wide Complex Trait Analysis)52 based on SNP array
data to estimate narrow sense h2. For the Framingham heart pedigree offspring
cohort, we used the additive polygenic model implemented in SOLAR to estimate
the heritability of IEAA and EEAA. In this additive polygenic model, heritability is
deﬁned as the proportion of phenotypic variance attributable to genetic variation.
Table 3 Several leukocyte telomere length associated SNPs are also associated with intrinsic epigenetic age acceleration in
blood
Study Chr Gene SNP A1 MAF Effect size (β) Meta P-value
LTL IEAA EEAA LTL IEAA EEAA
II 2 ACYP2 rs11125529 A 0.14 0.06 −0.06 −0.15 4.5 × 10−8 0.5 2.5 × 10−1
III 3 PXK rs6772228 A 0.06 −120 0.26 0.20 3.9 × 10−10 1.3 × 10−1 3.7 × 10−1
II 3 TERC rs10936599 T 0.24 −0.10 0.04 −0.07 2.5 × 10−31 0.7 4.7 × 10−1
III 3 rs1317082 G 0.23 −77 0.04 −0.08 1.3 × 10−19 0.7 4.6 × 10−1
II 4 NAF1 rs7675998 A 0.22 −0.07 −0.07 0.04 4.4 × 10−16 4.4 × 10−1 0.7
III 5 TERT rs7726159 A 0.33 73 0.67 0.27 4.7 × 10−17 9.5 × 10
−12
6.4 × 10−2
I 5 rs7705526 A 0.33 0.51 0.61 0.18 2.3 × 10−14 1.0 × 10−11 1.9 × 10−1
II 5 rs2736100 C 0.50 0.08 0.49 0.19 4.4 × 10−19 2.7 × 10−11 8.2 × 10−2
III 10 OBFC1 rs2487999 T 0.14 100 0.22 0.36 4.2 × 10−14 3.7 × 10–2 8.8 × 10–3
II 10 rs9420907 C 0.20 0.07 0.26 0.20 6.9 × 10−11 4.1 × 10–3 9.9 × 10−2
II 16 MPHOSPH6 rs2967374 A 0.22 0.05 0.23 0.12 2.7 × 10−7 7.8 × 10–3 2.9 × 10−1
II 19 ZNF208 rs8105767 G 0.32 0.05 −0.05 −0.13 1.1 × 10−9 0.5 1.7 × 10−1
III 20 BCL2L1 rs6060627 T 0.34 36 −0.13 0.11 6.5 × 10−7 7.7 × 10−2 2.6 × 10−1
II 20 RTEL1 rs755017 G 0.15 0.06 0.03 −0.08 6.7 × 10−9 0.8 0.5
P-values associated with age acceleration marked in italic if <0.05 and bold if <5.0 × 10−8
The table relates genome-wide signiﬁcant association results of leukocyte telomere length (LTL) to two epigenetic age acceleration measures, IEAA and EEAA. We queried the results of 14 SNPs across
10 distinct susceptibility loci associated with LTL from three large-scale studies: (I) meta-analysis association of LTL in chromosome 5 TERT only (N= 53,724)25, (II) a genome-wide meta-analysis of LTL
(N= 37,684)26, and (III) a genome-wide meta-analysis of LTL (N= 26,089)27. Each row presents a genome-wide signiﬁcant locus associated with LTL in a given study, except chromosome 16
MPHOSPH6 and chromosome 20 BCL2L1 just slightly below genome-wide signiﬁcance and highlighted by the corresponding studies as major ﬁndings. The listed markers are the leading SNPs with the
most signiﬁcant P-values associated with LTL at a given study and locus, sorted by chromosome, and position. Effect sizes of LTL association refer to the change in telomere lengths (ΔTL). Telomere
lengths were measured based on the relative telomere to single copy gene (T/S) ratios using standard qualitative PCR methods. A wide range of effect sizes for ΔTL across studies was due to different
scaling approaches applied to the measurements. The effect sizes for each age acceleration measure are in units of year
Chr= chromosome, A1= reference allele, MAF=minor allele frequency; effect sizes corresponding additive models
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To estimate the heritability of IEAA and EEAA using the meta-analysis results
from all European individuals from stage 1 (Fig. 1a) (studies 1–11, N = 8393), we
used LDSC analysis because it only requires GWAS summary statistics rather than
genotype type data. We chose the following options for LD score regression: 1000
Genome European data (phase I) downloaded from LDSC for specifying inde-
pendent variables (--ref-ld ﬂag) and weights (--w-ld ﬂag) in the regression. Prior to
estimation, we ﬁltered our markers to HapMap3 markers as downloaded and
suggested by LDSC, which could help align allele codes of our GWAS results with
other GWAS results for the genetic correlation analysis conducted later.
GCTA—REML analysis was used to estimate the heritability of IEAA and
EEAA among the WHI participants of African (AFR) or Hispanic ancestry. The
WHI sub-studies were genotyped on different platforms (Supplementary Table 2).
In order to combine the genotype data across the studies from WHI EMPC and
WHI BA23, we converted the MaCH dosage format into PLINK format and used
both genotyped and imputed markers in the analysis. We only used SNP markers
that could be found in all studies. We focused on high quality SNPs deﬁned based
on minor allele frequency (MAF) > 0.05, Hardy–Weinberg equilibrium (HWE) P
> 0.0001, and MaCH r2> 0.8, yielding ~4 million markers. In particular, we
increased the threshold of MAF to 10% in estimating the heritability of the
Hispanic group in order to ensure the convergence of the REML estimation
procedure. All analyses were adjusted for 4 principal components (PC).
GWAS meta-analysis. Our GWAS meta-analysis involved ~7.4 million SNPs or
INDEL variants, which were genotyped and imputed markers with the 1000
genomes haplotype reference panel. Prior to imputation, SNP quality was assessed
by MAF, HWE, and missingness rates across individuals (Supplementary Table 4).
The individual studies used IMPUTE253 with haplotypes phased using SHAPEIT54
or MaCH55 phased using Beagle56 or Minimac53 to impute SNP and INDEL
markers based on the 1000 Genomes haplotypes released in 2011 June or 2012
March. The quality of imputed markers was assessed by the Info measure >0.4 (in
IMPUTE2) or R2> 0.3 (in Minimac), and HWE P> 1.0 × 10−6. To increase reso-
lution for SNP association, a few genomic regions in the FHS cohort were also
imputed based the Haplotype Reference Consortium (N = 64,976)57. FHS used
linear mixed models to account for pedigree structure via a kinship matrix, as
implemented in R “lmekin” package. The BSGS cohort used Merlin/QTDT58 for
family-based association analysis. For other association analyses, we regressed the
age acceleration trait values on estimated genotype dosage (counts of test alleles) or
expected genotype dosage, implemented in Mach2QTL59, SNPTEST60, and PLINK.
All association models were adjusted for sex, to account for the higher epigenetic
age acceleration in men than women50, and also for PCs as needed. We included
variants with MAF ≥ 2%. SNPs were removed from an individual study if they
exhibited extreme effects (absolute regression coefﬁcient β> 30, Supplementary
Table 4).
We divided the meta-analysis into two since IEAA and EEAA differ across
racial/ethnic groups50. In one arm, we performed GWAS meta-analysis of IEAA
and EEAA, focusing on individuals of European ancestry (N = 8393, studies 1–11 in
Supplementary Table 1). We required a marker present in at least 5 study data sets
and combined the coefﬁcient estimates β from each study using a ﬁxed-effects
meta-analysis model weighted by inverse variance, as implemented in the software
Metal61. In the other arm, each SNP with suggestive association (P< 1.0 × 10−5) in
Europeans was subsequently evaluated in individuals of non-European ancestry (N
= 1514, studies 12–15 in Supplementary Table 1). A further meta-analysis
combined the GWAS ﬁndings from the two ancestries. We removed SNPs from the
meta-analysis if they exhibited highly signiﬁcant heterogeneity across studies
(Cochran Q I2 P-value ≤ 0.001), or co-located with CpG from the DNAm age
predictors according to the Illumina annotation ﬁle for the Illumina Inﬁnium 450K
array. We analyzed additional SNPs across all study sets to arrive at summary
statistics at the combined stage, which were needed for our summary statistics
based Mendelian randomization analyses. The quality of SNPs was also assessed
using the Cochran Q I2 P-value.
Linkage disequilibrium analysis. Regional SNP association results were visualized
with the software LocusZoom62. All linkage disequilibrium (LD) estimates pre-
sented in this article were calculated using individuals of European ancestry from
the 1000 genomes reference panel (released in Oct 2012).
Conditional analyses. The conditional analysis implemented in GCTA software52
was used to test whether a given genetic locus harbored multiple independent
causal variants. We conditioned on the leading SNP with the most signiﬁcant meta-
analysis P-value (Table 1). As reference panel for inferring the LD pattern we used
the N = 379 individuals with European ancestry from the 1000 genomes panel
released in December 2013. We deﬁned a SNP as having an additional association
if it remained signiﬁcant (P< 5 × 10−8) after conditioning on the leading SNP and
also met the additional criterion log10BF  6 for a signiﬁcant trans-ethnic
association.
Chromatin state annotations. For each leading SNP of a signiﬁcant locus, we used
the UCSC genome browser to display the primary chromatin states across 127 cell/
tissue lines at 200 bp resolution (Supplementary Fig. 8). The n = 127 diverse cell or
tissue lines were proﬁled by the NIH RoadMap Epigenomics22 (n = 111) and
ENCODE projects63 (n = 16). We used a 15-state chromatin model (from
ChromHMM) which is based on ﬁve histone modiﬁcation marks22.
Annotations for genome-wide signiﬁcant variants. We used the HaploReg
(version 4.1) tool64 to display characters of genome-wide signiﬁcant variants
Table 4 Genetic correlations with and causal effects of other complex traits on epigenetic age acceleration
IEAA EEAA
Genetic correlation MR-Egger regression Genetic correlation MR-Egger regression
Trait N rg Prg βcausal Pcausal rg Prg βcausal Pcausal
Category (I)
Waist circumference (cm) 232,101 0.10 2.2 × 10−2 1.99 9.6 × 10−2 0.15 9.0 × 10−4 −1.48 0.3
Waist-to-hip ratio 212,243 0.06 0.20 −0.31 0.9 0.14 2.7 × 10−3 −3.36 0.3
BMI (SD) 339,224 −0.01 0.9 1.40 5.6 × 10−2 0.08 0.3 0.40 0.7
Height (cm) 133,453 −0.02 0.7 0.004 0.1 0.13 2.8 × 10−3 0.004 0.2
Category (II)
HDL (SD) 188,577 −0.08 0.1 0.37 0.1 −0.12 2.0 × 10−2 0.11 0.7
Triglyceride (SD) 188,577 0.10 3.4 × 10−2 0.61 3.0 × 10−2 0.16 1.0 × 10−4 0.37 8.0 × 10−2
Type 2 diabetes 69,033 0.16 3.5 × 10−2 0.08 0.8 0.09 0.2 0.07 0.8
IBD 34,652 0.12 2.5 × 10−2 0.13 0.5 0.08 0.1 −0.35 0.2
Crohn’s disease 20,883 0.12 4.7 × 10−2 0.10 0.4 0.10 6.9 × 10−2 −0.29 7.6 × 10−2
Category (III and IV)
AMD subtype 45,818 0.03 0.2 −0.05 0.6 0.05 2.1 × 10−2 −0.04 0.7
Edu. attainment (years) 328,917 −0.01 0.8 2.35 0.3 −0.13 1.0 × 10−3 −4.63 7.8 × 10−2
Category (V)
Age at menarche (years) 252,514 −0.02 0.8 −1.03 4.1 × 10−3 −0.03 0.7 −0.17 0.7
Age at menopause (years) 69,360 −0.12 5.4 × 10−2 −0.43 3.5 × 10−3 −0.17 2.0 × 10−3 −0.21 0.3
Telomere length (T/S) 37,684 0.18 9.7 × 10−2 1.80 0.7 −0.16 0.1 3.20 0.3
Units of the traits associated with quantitative measures are displayed within parentheses. P-values <0.05 marked in bold
Results from cross-trait LDSC genetic correlation and Mendelian randomization Egger regression (MR-Egger) analyses for IEAA and EEAA are presented. The traits are ordered by category (I) GWAS of
anthropometric traits conducted by GIANT consortium, (II) GWAS of lipid, metabolic, and inﬂammatory outcomes and diseases, (III) GWAS of neurodegenerative and neuropsychiatric disorders, (IV)
cognitive functioning and educational attainment traits, and (V) longevity, reproductive aging and mitotic clock related traits. Complete results are presented in Supplementary Tables 12, 13 and 14. We
list the sample size of a study trait, Genetic correlation (rg) and its P-value (Prg ) as well the estimate of causal effect (βcausal) and its P-value (Pcausal) from MR-Egger regression
HDL = high-density lipoprotein, IBD = inﬂammatory bowel disease, AMD (subtype) = age-related macular degeneration (geographic atrophy), Edu. attainment = educational attainment, telomere length
refers to leukocyte telomere length
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including conserved regions by GERP and SiPhy scores, DNase tracks, involved
proteins and motifs, GWAS hits listed in NHGRI/EBI and functional annotation
listed in dbSNP database, as summarized in Supplementary Data 1.
Leukocyte cis-eQTL analyses. To evaluate cis-eQTL in blood, our cis-eQTL study
leveraged a large-scale blood expression data (n = 15,295) that came from ﬁve
broad categories of data. The ﬁrst category involved a large-scale eQTL analysis in
5257 individuals collected from the FHS pedigree cohort (of European ancestry)65.
Linear mixed models were performed for the eQTL analysis, adjusted for family
structure via random effects and adjusted gender, age, blood cell counts, PCs, and
other potential confounders via ﬁxed effects. The analysis was carried out using the
“pedigreemm” package of R. The second category involved the signiﬁcant cis-eQTL,
released from GTEx (version 6 in 2015)66. The expression data from GTEx involve
multiple tissues from 449 individuals of mostly (>80%) European ancestry. We
used the cis-eQTL results evaluated in 338 blood samples. The downloaded cis-
eQTL results only list signiﬁcant results (FDR q< 0.05), according to a permuta-
tion test based threshold that corrected for multiple comparisons across genes and
tissue types. The third category involved the cis-eQTL results from LSMeta67,
which was a large-scale eQTL meta-analysis in 5331 blood samples collected from
7 studies including our study cohort inChianti. We downloaded the cis-eQTL
results from http://genenetwork.nl/bloodeqtlbrowser/. The fourth and ﬁfth cate-
gories were discovery and replication samples from an eQTL analysis in peripheral
blood68, respectively. The publicly released cis-eQTL results only involved the 9640
most signiﬁcant (FDR q < 0.01) cis-eQTL results (corresponding to 9640 signiﬁcant
genes) from the discovery sample. The fourth category involved the expression data
of 2494 twins from the NTR cohort. The ﬁfth category involved 1895 unrelated
individuals from the NESDA cohort.
For all ﬁve categories of blood data, the cis-window surrounding each SNP
marker was deﬁned as ±1Mb. We deﬁned a signiﬁcant cis-eQTL relationship by
imposing the following criteria: (a) FDR q < 0.05 for categories 1–3, (b) FDR q<
0.01 for categories 4 and 5.
SMR analysis. SMR23 uses SNPs as instrumental variables to test for a direct
association between an exposure variable and an outcome variable, irrespective of
potential confounders. Unlike conventional Mendelian randomization analysis, the
SMR test uses summary-level data for both SNP-exposure and SNP-outcome that
can come from different GWAS studies23. We tested the expression levels of the
eleven candidate genes identiﬁed in our leukocyte cis-eQTL analysis.
SMR deﬁnes a pleiotropic association as association between gene expression
and a test trait due to pleiotropy or causality (Supplementary Fig. 12a, b). A
signiﬁcant SMR test P-value does not necessarily mean that gene expression and
the trait are affected by the same underlying causal variant, as the association could
possibly be due to the top associated cis-eQTL being in LD with two distinct causal
variants. Zhu et al.23 deﬁne the scenario of several causal variants, which is of less
biological interest than pleiotropy, as “linkage” and proposed a statistical test
“HEIDI” for distinguishing it from pleiotropy. The null hypothesis of the HEIDI
test corresponds to desirable causal scenarios. Thus, a non-signiﬁcant P-value
(deﬁned here as P ≥ 0.01) of the HEIDI test is a desirable ﬁnding. Conversely, a
signiﬁcant HEIDI test P-value indicates that at least two linked causal variants
affect both gene expression and epigenetic age acceleration (Supplementary
Fig. 12c).
To test the association of a given gene expression with age acceleration, we used
summary level cis-eQTL results from (1) FHS, (2) GTEx, and (3) LSMeta (total: N
= 10,906).
We included the cis-SNPs (with MAF ≥ 0.10) within a test gene (±1Mb). We
selected the cis-SNPs as instrumental markers as follows: cis-eQTL FDR< .05 for
GTEx, cis-eQTL P = 1 × 10−6 for the two large-scale studies: LSMeta and FHS. All
signiﬁcant SNP-gene pairs were subjected to the HEIDI analysis. The analysis
involves the summary data of the cis-SNPs surrounding the instrumental markers
and the LD pattern evaluated from a reference panel. We used the 1000 genome
individuals with ancestry of European (N = 379) released in December 2013 as the
reference panel, imposed an LD threshold of 0.9 and selected a default setting based
on a chi-square (χ21) test statistic threshold of 10 for SNP pruning. The GWAS
summary data were based on the meta-analysis results at the combined stage. As a
sensitivity check, we repeated the HEIDI analysis using the summary GWAS data
of individuals with European ancestry (studies 1–11).
Mendelian randomization analysis for LTL and IEAA. We gathered the summary
statistics from three large-scale meta-analysis studies for association with LTL,
including (I) the association results of 484 SNPs located in TERT locus from the
study conducted by Bojesen et al.25 (N = 53,724 individuals of European ancestry),
(II) the GWAS summary data from the study conducted by Codd et al.26 (N =
37,684 individuals of European ancestry) downloaded from the European Network
for Genetic and Genomic Epidemiology consortium (ENGAGE, see URL) and (III)
the association results of 4 SNPs at P< 5.0 × 10−8 and 1 SNPs at P< 1.0 × 10−6
listed in Table 1 from the study conducted by Pooley et al.27 (N = 26,089 indivi-
duals of European ancestry). In the ﬁrst study, the effect sizes were available for
change in telomere length (ΔTL> 0 indicating a test allele associated with longer
LTL) and fold change in telomere length (>1 indicating a test allele associated with
longer LTL). We used the effect sizes with respect to ΔTL in our analysis. The other
two studies reported ΔTL in their summary data. All telomere lengths refer to the
relative telomere to single-copy gene (T/S) ratios using quantitative PCR methods
with different scaling approaches applied to each study. The summary data of the
second were used for bidirectional Mendelian randomization analysis. Summary
statistics of IEAA and EEAA were based on the association results from the
combined meta-analysis. Our SMR analysis used the summary data from studies I
and II. To compare the patterns between LTL associations and IEAA associations
at 5p15.33 TERT locus, we used the dense panel of SNP association results from
study I (484 SNPs), as depicted in Fig. 3b.
IEAA adjusted LTL in 5p15.33 TERT locus. To inspect the SNPs on TERT locus
affecting IEAA independent of LTL, we re-conducted the association analysis on a
subset (N = 785) individuals from the WHI for whom both DNA methylation data
and leukocyte telomere length measures were available. The study involved 457
individuals with European ancestry (from studies 3 and 5) and 328 individuals with
Africans ancestry (from study 12). For each study, association tests were performed
on IEAA and IEAA adjusted LTL, respectively. The results were combined by
ﬁxed-effects meta-analysis models.
Blood cell composition vs. variants in TERT. The imputed blood cell abundance
measures were related to SNPs in the TERT locus using 8 studies from two cohorts:
FHS (study 1) and WHI (studies 3–5 and 12–15, listed in Supplementary Table 1)
involving n = 5373 individuals. The following imputed blood cell counts were
analyzed: naive CD4+ T, naive CD8+ T, exhausted CD8+ T cells (deﬁned as CD28-
negative CD45R-negative), plasmablasts, CD4+ T, nature killer cells, monocytes,
and granulocytes. Blood cell proportions (CD8+ T cells, CD4+ T cells, NK cells, B
cells, and granulocytes) were estimated using Houseman’s estimation method
which is based on DNA methylation signatures from puriﬁed leukocyte samples49.
The percentage of exhausted CD8+ T cells (deﬁned as CD28−CD45RA− B cells) and
the number of naive CD8+ T cells (deﬁned as CD45RA+CCR7+ B cells) were
estimated using the advanced analysis option of the epigenetic clock software14. To
avoid confounding, the cell abundance measures were adjusted for chronological
age by forming residuals. For each study, the SNP association analysis was per-
formed using the same SNP makers from our genome-wide meta-analysis of IEAA
and EEAA. The results were combined across studies using the same ﬁxed-effects
meta-analysis model.
In vitro studies of hTERT in human ﬁbroblasts. Foreskins were obtained from
routine elective circumcision. The tissue was cut into small pieces and digested
overnight at 4 °C with Liberase, after which the epidermis was peeled away from
the dermis. Several pieces of dermis were placed face down in a plastic dish with
DMEM supplemented with 10% foetal calf serum, penicillin, streptomycin, and
gentamycin. After incubation at 37 °C with 5% carbon dioxide for a week, ﬁbro-
blasts that emerged from the tissues were collected and expanded in fresh dishes.
Recombinant retroviruses bearing empty vector (pBabePuro) or the hTERT
gene; pBabePurohTERT (kind gift from Robert Weinberg) were prepared by
transfecting Phoenix A cells grown in DMEM supplemented with 10% foetal calf
serum, using Profection Mammalian Transfection System (Promega Cat. No:
E1200). Forty-eight hours post-transfection, recombinant viruses in the media were
collected, ﬁltered through 0.2 micrometer ﬁlter and mixed with Polybrene (Santa
Cruz Biotechnology Cat. No: 134220) to a ﬁnal concentration of 8 µg/ml. Media of
primary ﬁbroblasts were removed and replaced with the virus mix. After 24 h at 37
°C (5% carbon dioxide), the virus mix was removed and fresh media (DMEM
+10% foetal calf serum) containing 1 µg/ml puromycin was added to kill uninfected
cells. Puromycin selection was stopped after 4 days post-selection, when all cells in
the un-infected control plates were killed. Successfully infected ﬁbroblast were
collected, counted and 200,000 were seeded into 10 cm cell culture plates
containing DMEM supplemented with 10% foetal calf serum. When cells became
conﬂuent, they were collected by trypsinisation, counted and 200,000 were seeded
in fresh 10 cm plates. This cycle of culture, collecting and seeding was repeated
until the control cells senesced. The cell numbers were used to calculate population
doubling according to the following formula: Population doubling = 3.32[log(ﬁnal
cell number)—log(number of cell seeded)]. In parallel to the proliferating culture
of cells described above, separate plates of infected ﬁbroblasts (pBabePuro and
pBabePurohTERT) were grown without passaging throughout the experiment, but
with regular media change three times a week for the duration of the experiment.
These were regarded as “static” cultures as they were not passed since being seeded
from the start of the experiment. DNA from all the collected cells were extracted
according to the procedure described in the QIAamp DNA Mini Kit (Qiagen Cat.
No. 51306). The DNA was subjected to DNA methylation analyses using the
Illumina 450 arrays.
GWAS based enrichment analysis with MAGENTA. We used the MAGENTA
software29 to assess whether our meta-analysis GWAS results of epigenetic age
acceleration are enriched for various gene sets, e.g., KEGG pathways, Gene
Ontology (GO) terms, such as biological processes or molecular functions. To
assign genes to SNPs, we extended gene boundaries to ±50 kb. For computational
reasons, we removed categories that did not contain any genes related to age
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acceleration at a level of P< 1.0 × 10−3 or that contained fewer than 10 genes. The
cutoffs of gene set enrichment analysis (GSEA) in the MAGENTA algorithm were
set at 95th and 75th percentiles which are the default parameter values for a general
phenotype and for a highly polygenic trait, respectively29.
Initially, empirical P-values were estimated based on 10,000 permutations. For
signiﬁcant gene sets (empirical P< 1.0 × 10−4), we estimated the ﬁnal empirical P-
value using one million permutations. We only report gene sets whose false
discovery rate FDR (calculated by MAGENTA) was <0.20.
LDSC genetic correlation analysis. We performed cross-trait LD score regres-
sion30 to relate IEAA/EEAA to various complex traits (27 GWAS summary data
across 23 distinct phenotypes). The GWAS results for IEAA and EEAA were based
on the summary data at stage 1 analysis.
The following is a terse description of the 27 published GWAS studies. Two
GWAS results in individuals of European ancestry came from the GIANT
consortium on body fat distribution: waist circumference and hip to waist ratio.
GWAS results of BMI and height also from the GIANT consortium. Further, we
used published GWAS results from inﬂammatory bowel disorder (IBD) and its two
subtypes: Crohn’s disease and ulcerative colitis, lipid levels, metabolic outcomes
and diseases: insulin and glucose levels, type 2 diabetes (stage 1 results) phenotype,
age-related macular degeneration (neovascular and geographic atrophy),
Alzheimer’s disease (stage 1 results), attention deﬁcit hyperactivity disorder
(ADHD), bipolar disorder, major depressive disorder, schizophrenia, education
attainment, age at menarche, age at menopause, LTL and longevity. The summary
data of LTL was based the GWAS conducted by Codd et al.26, as described in an
earlier section. A description of other published GWAS study can be found in
Supplementary Note 4.
As recommend by LDSC, we ﬁltered to HapMap3 SNPs for each GWAS
summary data, which could help align allele codes of our GWAS results with other
GWAS results for the genetic correlation analysis. In our GWAS studies with GC-
correction, we constrained the intercept terms with the --intercept–h2 and
–intercept-gencov ﬂags. Toward this end, we used the heritability analysis of the
LDSC regression to estimate intercept terms. Additional genetic correlation
analysis was performed via the LD Hub software tool31 that allowed us to analyze
233 traits. The built-in LDSC platform automatically removed all variants in the
MHC region on chromosome 6 (26–34 MB).
MR-Egger regression. Under a weaker set of assumptions than typically used in
Mendelian randomization (MR), an adaption of Egger regression can be used to
detect and correct for the bias due to directional pleiotropy28. While the standard
method of MR estimation, two-stage least squares, may be biased when directional
pleiotropy is present, MR-Egger regression can provide a consistent estimate of the
causal effect of an exposure (e.g., age at menopause) on an outcome trait (e.g.,
epigenetic age acceleration). In testing the regression model, we used the leading
variants (P< 5.0 × 10−8 or their surrogates) from each GWAS locus associated with
the exposure, as instrumental variables. We performed LD-based clumping pro-
cedure in PLINK with a threshold of r2 set at 0.1 in a window size of 250 kb to yield
the leading variants present in both GWAS summary data sets (for exposure and
outcome), as needed. For those traits showing signiﬁcant causal effects on IEAA (or
EEAA), we performed a sensitivity analysis (stratiﬁed analysis) to check if the
signiﬁcant associations spuriously resulted from the instrumental variables (SNPs)
co-locating (±1Mb) with CpG sites from the DNAm age estimators. The random
effects model meta-analysis was performed using “MendelianRandomization” R
package.
GWAS-based overlap analysis. Our GWAS-based overlap analysis related gene
sets found by our GWAS of epigenetic age acceleration with analogous gene sets
found by published GWAS of various phenotypes. We used the MAGENTA
software to calculate an overall GWAS P-value per gene, which is based on the
most signiﬁcant SNP association P-value within the gene boundary (±50 kb)
adjusted for gene size, number of SNPs per kb, and other potential confounders29.
To assess the overlap between age acceleration and a test trait, we selected the top
2.5% (roughly 500 genes ranked by P-values) and top 10 % genes (roughly 1900
genes) for each trait and calculated one-sided hypergeometric P-values20,69. In
contrast with the genetic correlation analysis, GWAS based overlap analysis does
not keep track of the signs of SNP allele associations.
We performed the overlap analysis for all the 23 complex traits used in the
genetic correlation LDSC analysis and a few more studies that we were not able to
conduct the LDSC analysis due to small sample size (N< 5000), negative
heritability estimates or the entire study population from non-European ancestry.
The additional traits included modiﬁers of Huntington’s disease motor onset,
Parkinson’s disease and cognitive functioning traits (Supplementary Note 4).
URLs. URLs of databases and bioinformatics tools used throughout the masnucript
are: 1000 genome project, http://www.1000genomes.org/, DNAm age, http://labs.
genetics.ucla.edu/horvath/htdocs/dnamage/, ENGAGE, https://downloads.lcbru.le.
ac.uk/, EIGENSTRAT, http://genepath.med.harvard.edu/~reich/Software.htm,
GTEx, http://www.gtexportal.org/home/documentationPage#AboutGTEx, GIANT,
https://www.broadinstitute.org/collaboration/giant/index.php/Main_Page,
HaploReg, http://www.broadinstitute.org/mammals/haploreg/haploreg.php, HRC,
http://www.sanger.ac.uk/science/collaboration/haplotype-reference-consortium,
HRS, http://hrsonline.isr.umich.edu/, Illumina Inﬁnium 450K array annotation,
http://support.illumina.com/downloads/
inﬁnium_humanmethylation450_product_ﬁles.html.
IMPUTE2, https://mathgen.stats.ox.ac.uk/impute/impute_v2.html, LD score
Regression, https://github.com/bulik/ldsc, LD Hub, http://ldsc.broadinstitute.org/
ldhub/, Locuszoom, http://csg.sph.umich.edu/locuszoom/, METAL, http://csg.sph.
umich.edu/abecasis/Metal/, MAGENTA, https://www.broadinstitute.org/mpg/
magenta/, NESDA, http://www.nesda.nl/en/, NTR, http://www.tweelingenregister.
org/en/, PLINK, http://pngu.mgh.harvard.edu/~purcell/plink/, R metafor, http://
cran.r-project.org/web/packages/metafor/, R WGCNA, http://labs.genetics.ucla.
edu/horvath/CoexpressionNetwork/, SHAPEIT, https://mathgen.stats.ox.ac.uk/
genetics_software/shapeit/shapeit.html, SNPTEST, https://mathgen.stats.ox.ac.uk/
genetics_software/snptest/snptest.html, YFS, http://youngﬁnnsstudy.utu.ﬁ/index.
html,
Data availability. The FHS data are available at dbGaP under the accession
numbers phs000342 and phs000724. The TwinsUK DNA methylation data are
available through the NCBI Gene Expression Omnibus (GEO) under accession
number GSE62992. Individual level genotype and phenotype data from TwinsUK
are not permitted to be shared or deposited due to the original consent given at the
time of data collection. However, genotype, DNA methylation, and phenotype data
can be accessed through application to the TwinsUK data access committee (http://
www.twinsuk.ac.uk/data-access/submission-procedure/). The WHI data are avail-
able at dbGaP under the accession numbers phs000200.v10.p3. The phenotypes of
BLSA and inChianti data are available at dbGaP under the accession numbers
phs000215.v2.p1. LBC methylation data have been submitted to the European
Genome-phenome Archive under accession number EGAS00001000910; pheno-
typic data are available at dbGaP under the accession number phs000821.v1.p1.
BSGS methylation data are available from GEO accession number GSE56105.
Additional information can be found in Supplementary Note 1 and Supplementary
Table 3.
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